JP2024514339A - がんを治療する化合物、組成物、及び方法 - Google Patents
がんを治療する化合物、組成物、及び方法 Download PDFInfo
- Publication number
- JP2024514339A JP2024514339A JP2023564025A JP2023564025A JP2024514339A JP 2024514339 A JP2024514339 A JP 2024514339A JP 2023564025 A JP2023564025 A JP 2023564025A JP 2023564025 A JP2023564025 A JP 2023564025A JP 2024514339 A JP2024514339 A JP 2024514339A
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- mmol
- resulting mixture
- group
- room temperature
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163175974P | 2021-04-16 | 2021-04-16 | |
| US63/175,974 | 2021-04-16 | ||
| US202163281493P | 2021-11-19 | 2021-11-19 | |
| US63/281,493 | 2021-11-19 | ||
| PCT/US2022/025083 WO2022221704A1 (en) | 2021-04-16 | 2022-04-15 | Compounds, compositions and methods of treating cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024514339A true JP2024514339A (ja) | 2024-04-01 |
| JP2024514339A5 JP2024514339A5 (cg-RX-API-DMAC7.html) | 2026-06-24 |
Family
ID=81580947
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023564025A Pending JP2024514339A (ja) | 2021-04-16 | 2022-04-15 | がんを治療する化合物、組成物、及び方法 |
Country Status (14)
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4359381A4 (en) * | 2021-06-21 | 2025-04-30 | Nimbus Clio, Inc. | Cbl-b modulators and uses thereof |
| US20250042896A1 (en) * | 2021-10-29 | 2025-02-06 | Hainan Simcere Zaiming Pharmaceutical Co., Ltd. | Polycyclic compound as cbl-b inhibitor |
| US12187709B2 (en) | 2021-11-05 | 2025-01-07 | Genentech, Inc. | Lactams as CBL-B inhibitors selective over C-CBL |
| WO2023205180A1 (en) | 2022-04-19 | 2023-10-26 | Nurix Therapeutics, Inc. | Biomarkers for cbl, and compositions and methods for their use |
| WO2023250097A1 (en) | 2022-06-22 | 2023-12-28 | Nurix Therapeutics, Inc. | Combination therapies with cbl-b inhibitor compounds and antiemetic agents |
| EP4554586A1 (en) * | 2022-07-12 | 2025-05-21 | Hotspot Therapeutics, Inc. | Cbl-b inhibitors and anti-pd1/anti-pd-l1 for use in the treatment of cancer |
| JP2025523682A (ja) * | 2022-07-12 | 2025-07-23 | ホットスポット セラピューティクス インコーポレイテッド | 複素環式化合物の調製方法 |
| KR20250085707A (ko) * | 2022-07-12 | 2025-06-12 | 핫스팟 세라퓨틱스, 인크. | Cbl-b 조절제로서의 트리아진 유도체의 고체 형태 |
| JP2025523058A (ja) * | 2022-07-12 | 2025-07-17 | ホットスポット セラピューティクス インコーポレイテッド | Clb-b阻害剤と追加の治療剤を併用した細胞増殖関連病態の処置 |
| WO2024015863A1 (en) * | 2022-07-12 | 2024-01-18 | Hotspot Therapeutics, Inc. | Cbl-b inhibitor, compositions comprising a cbl-b inhibitor in a method of treating a disease associated with cell proliferation |
| CN119630662A (zh) * | 2022-07-18 | 2025-03-14 | 英矽智能科技知识产权有限公司 | Cbl-b抑制剂及其应用方法 |
| WO2024077244A1 (en) * | 2022-10-07 | 2024-04-11 | Hotspot Therapeutics, Inc. | Compounds, compositions and methods of treating disorders |
| WO2024077236A1 (en) * | 2022-10-07 | 2024-04-11 | Hotspot Therapeutics, Inc. | Compounds, compositions and methods of treating disorders |
| WO2024086730A1 (en) * | 2022-10-19 | 2024-04-25 | Hotspot Therapeutics, Inc. | Heterocyclic cbl-b inhibitors for the treatment of cancer |
| US20260193251A1 (en) | 2022-11-16 | 2026-07-09 | Pfizer Inc. | Substituted Bicyclic Pyridone Derivatives |
| WO2024131939A1 (en) * | 2022-12-23 | 2024-06-27 | Insilico Medicine Ip Limited | Cbl-b inhibitors and methods of uses thereof |
| EP4653436A1 (en) * | 2023-01-19 | 2025-11-26 | Guangzhou Yufan Nantu Biotechnologies Co., Ltd | Heterocyclic compounds, preparation method therefor and use thereof |
| WO2024153246A1 (zh) * | 2023-01-20 | 2024-07-25 | 海南先声再明医药股份有限公司 | 取代的三环化合物及其应用 |
| WO2024227436A1 (en) * | 2023-05-04 | 2024-11-07 | InventisBio Co., Ltd. | Compounds, preparation methods and uses thereof |
| WO2025067342A1 (zh) * | 2023-09-27 | 2025-04-03 | 北京望实智慧科技有限公司 | 用作Cbl-b抑制剂的化合物 |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019131575A1 (ja) * | 2017-12-26 | 2019-07-04 | 住友化学株式会社 | 複素環化合物及びそれを含有する有害節足動物防除剤 |
| JP2019535689A (ja) * | 2016-10-27 | 2019-12-12 | バイエル アクチェンゲゼルシャフトBayer Aktiengesellschaft | 4,5−縮環1,2,4−トリアゾロン |
| WO2020210508A1 (en) * | 2019-04-09 | 2020-10-15 | Nurix Therapeutics, Inc. | 3-substituted piperidine compounds for cbl-b inhibition, and use of a cbl-b inhibitor in combination with a cancer vaccine and/or oncolytic virus |
| JP2020169215A (ja) * | 2020-07-15 | 2020-10-15 | 住友化学株式会社 | 複素環化合物を用いる有害節足動物防除方法 |
| WO2020264398A1 (en) * | 2019-06-26 | 2020-12-30 | Nurix Therapeutics, Inc. | Substituted benzyl-triazole compounds for cbl-b inhibition, and further uses thereof |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3740837A1 (de) * | 1987-11-27 | 1989-06-08 | Schering Ag | Substituierte bicyclische triazole, verfahren zu ihrer herstellung und ihre verwendung als herbizide mittel |
| BRPI0814441A2 (pt) * | 2007-07-19 | 2015-07-14 | Schering Corp | Compostos de amida heterocíclica como inibidores de proteína cinase |
| KR20100072266A (ko) * | 2007-10-24 | 2010-06-30 | 머크 샤프 앤드 돔 코포레이션 | 헤테로사이클 페닐 아미드 t-형 칼슘 채널 길항제 |
| EP3573971A1 (en) * | 2017-01-26 | 2019-12-04 | Araxes Pharma LLC | 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer |
| IL301690A (en) * | 2020-10-16 | 2023-05-01 | Dana Farber Cancer Inst Inc | Piperidinyl small molecule degraders of helios and methods of use |
| KR20250085707A (ko) * | 2022-07-12 | 2025-06-12 | 핫스팟 세라퓨틱스, 인크. | Cbl-b 조절제로서의 트리아진 유도체의 고체 형태 |
| WO2024015863A1 (en) * | 2022-07-12 | 2024-01-18 | Hotspot Therapeutics, Inc. | Cbl-b inhibitor, compositions comprising a cbl-b inhibitor in a method of treating a disease associated with cell proliferation |
| JP2025523682A (ja) * | 2022-07-12 | 2025-07-23 | ホットスポット セラピューティクス インコーポレイテッド | 複素環式化合物の調製方法 |
| EP4554586A1 (en) * | 2022-07-12 | 2025-05-21 | Hotspot Therapeutics, Inc. | Cbl-b inhibitors and anti-pd1/anti-pd-l1 for use in the treatment of cancer |
| JP2025523058A (ja) * | 2022-07-12 | 2025-07-17 | ホットスポット セラピューティクス インコーポレイテッド | Clb-b阻害剤と追加の治療剤を併用した細胞増殖関連病態の処置 |
-
2022
- 2022-04-15 US US18/286,966 patent/US20240228482A1/en active Pending
- 2022-04-15 TW TW111114558A patent/TW202309023A/zh unknown
- 2022-04-15 CA CA3215395A patent/CA3215395A1/en active Pending
- 2022-04-15 WO PCT/US2022/025083 patent/WO2022221704A1/en not_active Ceased
- 2022-04-15 MX MX2023012245A patent/MX2023012245A/es unknown
- 2022-04-15 PE PE2023002860A patent/PE20240767A1/es unknown
- 2022-04-15 JP JP2023564025A patent/JP2024514339A/ja active Pending
- 2022-04-15 KR KR1020237039416A patent/KR20240037184A/ko active Pending
- 2022-04-15 IL IL307732A patent/IL307732A/en unknown
- 2022-04-15 AU AU2022256514A patent/AU2022256514A1/en active Pending
- 2022-04-15 BR BR112023021068A patent/BR112023021068A2/pt unknown
- 2022-04-15 EP EP22721591.0A patent/EP4323358A1/en active Pending
-
2023
- 2023-10-13 CL CL2023003068A patent/CL2023003068A1/es unknown
- 2023-11-16 CO CONC2023/0015484A patent/CO2023015484A2/es unknown
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2019535689A (ja) * | 2016-10-27 | 2019-12-12 | バイエル アクチェンゲゼルシャフトBayer Aktiengesellschaft | 4,5−縮環1,2,4−トリアゾロン |
| WO2019131575A1 (ja) * | 2017-12-26 | 2019-07-04 | 住友化学株式会社 | 複素環化合物及びそれを含有する有害節足動物防除剤 |
| WO2020210508A1 (en) * | 2019-04-09 | 2020-10-15 | Nurix Therapeutics, Inc. | 3-substituted piperidine compounds for cbl-b inhibition, and use of a cbl-b inhibitor in combination with a cancer vaccine and/or oncolytic virus |
| WO2020264398A1 (en) * | 2019-06-26 | 2020-12-30 | Nurix Therapeutics, Inc. | Substituted benzyl-triazole compounds for cbl-b inhibition, and further uses thereof |
| JP2020169215A (ja) * | 2020-07-15 | 2020-10-15 | 住友化学株式会社 | 複素環化合物を用いる有害節足動物防除方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20240037184A (ko) | 2024-03-21 |
| WO2022221704A1 (en) | 2022-10-20 |
| AU2022256514A1 (en) | 2023-10-19 |
| EP4323358A1 (en) | 2024-02-21 |
| TW202309023A (zh) | 2023-03-01 |
| CA3215395A1 (en) | 2022-10-20 |
| MX2023012245A (es) | 2024-03-11 |
| PE20240767A1 (es) | 2024-04-17 |
| CO2023015484A2 (es) | 2023-11-30 |
| BR112023021068A2 (pt) | 2024-01-23 |
| IL307732A (en) | 2023-12-01 |
| US20240228482A1 (en) | 2024-07-11 |
| CL2023003068A1 (es) | 2024-05-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20240037184A (ko) | 화합물, 조성물 및 암 치료 방법 | |
| US11780845B2 (en) | FGFR inhibitors and methods of use thereof | |
| TWI874443B (zh) | KRas G12D抑制劑 | |
| CA2905012C (en) | Substituted 7-azabicycles and their use as orexin receptor modulators | |
| JP6494622B2 (ja) | カゼインキナーゼ1d/e阻害剤としての置換された4,5,6,7−テトラヒドロピラゾロ[1,5−a]ピラジン誘導体 | |
| US20240150377A1 (en) | Modulators of cystic fibrosis transmembrane conductance regulator | |
| JP2024505261A (ja) | Cdk2阻害剤およびその使用方法 | |
| WO2023067515A1 (en) | Thiadiazolyl compounds as dna polymerase theta inhibitors | |
| CN112368278A (zh) | Rip1抑制性化合物以及制备和使用其的方法 | |
| CA3196901A1 (en) | Macrocyclic urea orexin receptor agonists | |
| BR112021011147A2 (pt) | Benzamidas de derivados de pirazolil-amino-pirimidinila e composições e métodos das mesmas | |
| AU2018252099B2 (en) | Fluorine-substituted indazole compounds and uses thereof | |
| TW202330530A (zh) | 咪唑并嗒𠯤il-17抑制劑化合物(二) | |
| TW201710250A (zh) | 經取代之喹喏啉衍生物 | |
| EP4562016A2 (en) | Cdk2 inhibitors and methods of using the same | |
| AU2021300831A1 (en) | RIP1k inhibitors | |
| JP7627269B2 (ja) | RORγt阻害剤、その製造方法及び使用 | |
| CN117751115A (zh) | 化合物、组合物和治疗癌症的方法 | |
| EP4426285A1 (en) | Histone deacetylase 6 inhibitor compounds and uses thereof | |
| WO2025193691A1 (en) | Bicyclic heteroaromatic compounds as trpml modulators | |
| HK40076948A (en) | Kras g12d inhibitors | |
| HK40068242A (en) | Rip1 inhibitory compounds and methods for making and using the same | |
| HK40068242B (en) | Rip1 inhibitory compounds and methods for making and using the same | |
| HK40082783A (en) | Rip1 inhibitory compounds and methods for making and using the same | |
| HK40015368A (en) | Fluorine-substituted indazole compounds and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240329 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250415 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20250415 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20260128 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20260216 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20260514 |
|
| A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20260514 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20260702 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20260721 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20260723 |